Theravance Biopharma Inc TBPH 深 沪
等待开盘 08-20 09:30:00 美东时间
16.99
+0.040
+0.24%
华盛通- 最 高17.00
- 今 开16.96
- 成交量 25.79万股
- 最 低 16.96
- 昨 收 16.95
- 总市值 8.82亿
- 52周最高 21.03
- 市盈率 静 8.26
- 换手率 0.50%
- 52周最低 13.08
- 委 比 -79.40%
- 总股本 5191.88万
- 历史最高 43.44
- 量 比 0.71
- 振 幅 0.24%
- 历史最低 6.10
- 每 手 1
- 风险率 1.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Zymeworks gains following addition to Citi catalyst watch
Zymeworks (ZYME) is up ~2% in Monday trading after Citi added the stock to its 90-day catalyst watch list. The bank sees shares rising due to an August 25 FDA action date for zanidatamab, sold as Ziih...
08-11 00:05
Theravance Biopharma Q2 Adj. EPS $0.18 Beats $0.05 Estimate, Sales $20.731M Miss $21.600M Estimate
Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.05 by 260 percent. This is a 325 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $20.731 million...
08-10 20:35
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
Zymeworks Inc. announced it will report its second quarter 2026 financial results on August 6, 2026, after market close. Due to the proposed acquisition of Theravance Biopharma, the company will not host a second quarter earnings conference call. Zymeworks, a global biotechnology company, focuses on managing licensed healthcare assets and developing innovative biotherapeutics for diseases like cancer, inflammation, and autoimmune disorders. The c...
07-16 10:00
美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
HC Wainwright & Co. Downgrades Theravance Biopharma to Neutral, Raises Price Target to $17
HC Wainwright & Co. analyst Douglas Tsao downgrades Theravance Biopharma (NASDAQ:TBPH) from Buy to Neutral and raises the price target from $15 to $17.
07-07 19:41
Theravance downgraded at Jones on Zymeworks acquisition
Jones Trading has downgraded Theravance Biopharma (TBPH) to hold from buy following the announcement earlier Monday that Zymeworks (ZYME) is acquiring the company in a $929M deal. Analyst Debanjana Ch...
06-30 02:36
BTIG Downgrades Theravance Biopharma to Neutral
BTIG analyst Julian Harrison downgrades Theravance Biopharma (NASDAQ:TBPH) from Buy to Neutral.
06-29 23:31
Theravance Biopharma Inc：BTIG将其评级从买入下调至中性
BTIG将生物制药公司Theravance的股票评级从“买入”下调至“中性”。 译文内容由第三方软件翻译。 声明：市场有风险，投资需谨慎。本文由AI大模型基于公...
06-29 21:43
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
Zymeworks Inc. (NASDAQ:ZYME) said Monday it has agreed to acquire Theravance Biopharma Inc. (NASDAQ:TBPH) in an all-cash transaction valued at about $929 million. The deal, which aims to bolster Zymeworks’ commercial portfolio, will pay $17 per share for Theravance Biopharma shares. The companies ex...
06-29 21:20
